EUVIMEDEUVIMED entdecken
Crossref

Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma

Chengfang Tang, Chu Tang, Xuanchi Zhu, Simeng Wang, Yuan Yang, Yu Miao, Xiaoyao Zhao, Lina Jia, Jingyu Yang, Yang Su, Lihui Wang, Chunfu Wu iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Chengfang Tang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Axin Protein, Carcinoma, Hepatocellular, Liver Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 'Xingliao Talents' Program of Liaoning Province, Natural Science Foundation of Shenyang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose As a highly heterogeneous cancer, hepatocellular carcinoma (HCC) shows different response rates to the multi‐kinase inhibitor lenvatinib. Thus, it is important to explore genetic biomarkers for precision lenvatinib therapy in HCC. Experimental Approach The effect and mechanism of AXIN1 mutation on HCC were revealed by cell proliferation assay, long‐term clone formation assay, sphere formation assay and small molecule inhibitor library screening. A new therapeutic strategy targeting HCC with AXIN1 mutation was evaluated in humanized models (patient‐derived xenograft [PDX] and patient‐derived organoid [PDO]). Key Results Based on The Cancer Genome Atlas (TCGA) data, we screened 6 most frequently lost tumour suppressor genes in HCC (TP53, ARID1A, AXIN1, CDKN2A, ARID2 and PTEN) and identified AXIN1 as the most crucial gene for lenvatinib sensitivity. Further study showed that AXIN1‐knockout HCC cells had a more malignant phenotype and lower sensitivity to lenvatinib in vitro and in vivo . Mechanistically, the WNT pathway and its target gene c‐Myc were activated when AXIN1 was missing, and the expression of tumour suppressor p15 was inhibited by transcription co‐repressors c‐Myc and Miz‐1, resulting in the exacerbation of the resistant phenotype. Screening of a library of epigenetic‐related enzyme inhibitors showed that a KDM5B inhibitor up‐regulated p15 expression, leading to increased sensitivity to lenvatinib in vitro and in vivo . Conclusion and Implications AXIN1‐deficient patients have a lower response to lenvatinib, which may be associated with suppression of p15 mediated by WNT pathway activation. KDM5B inhibitors can restore p15 levels, resulting in efficient killing of resistant cells in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Axin ProteinCarcinoma, HepatocellularLiver NeoplasmsProtein Kinase InhibitorsDrug Resistance, NeoplasmXenograft Model Antitumor AssaysOrganoidsTumor Cells, CulturedPrimary Cell CultureJumonji Domain-Containing Histone DemethylasesWnt ProteinsCyclin-Dependent Kinase Inhibitor p15Signal TransductionPrecision MedicineBiomarkers, TumorHumansAnimalsMiceGenes, Tumor SuppressorGene Expression Regulation, NeoplasticEpigenesis, GeneticMaleMice, Inbred BALB CRNA-SeqLoss of Function Mutation

Stichwörter der Autor:innen

AXIN1 mutationKDM5Bbiomarkerhepatocellular carcinoma (HCC)lenvatinib

Substanzen

Axin ProteinJumonji Domain-Containing Histone DemethylasesWnt ProteinsCyclin-Dependent Kinase Inhibitor p15Protein Kinase InhibitorsBiomarkers, TumorAXIN1 protein, humanKDM5B protein, humanNuclear ProteinsRepressor Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
  • Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi, China.
  • Clinical Laboratory, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Chunfu Wu

Förderung

  • National Natural Science Foundation of China
  • 'Xingliao Talents' Program of Liaoning Province
  • Natural Science Foundation of Shenyang

Zitieren

APA

Tang, C., Tang, C., Zhu, X., Wang, S., Yang, Y., Miao, Y., Zhao, X., Jia, L., Yang, J., Su, Y., Wang, L., & Wu, C. (2025). Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. British Journal of Pharmacology. https://doi.org/10.1111/bph.17413

Vancouver

Tang C, Tang C, Zhu X, Wang S, Yang Y, Miao Y, et al. Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma. British Journal of Pharmacology. 2025. doi:10.1111/bph.17413

BibTeX
@article{Tang2025,
  author = {Tang, Chengfang and Tang, Chu and Zhu, Xuanchi and Wang, Simeng and Yang, Yuan and Miao, Yu and Zhao, Xiaoyao and Jia, Lina and Yang, Jingyu and Su, Yang and Wang, Lihui and Wu, Chunfu},
  title = {Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17413}
}
Kostenlos starten →